Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Lymphoma, T-Cell, Peripheral
  • Neoplasm Recurrence, Local
  • Sulfonamides

abstract

  • Monotherapy with belinostat produced complete and durable responses with manageable toxicity in patients with relapsed or refractory PTCL across the major subtypes, irrespective of number or type of prior therapies. These results have led to US Food and Drug Administration approval of belinostat for this indication.

publication date

  • August 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5087312

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.2782

PubMed ID

  • 26101246

Additional Document Info

start page

  • 2492

end page

  • 9

volume

  • 33

number

  • 23